DRIO DarioHealth

Market News Alert: DarioHealth Secures Significant New Agreement, Expanding Growth in the $1.2 Trillion Dollar Cardiometabolic Market

Market News Alerts Updates: DarioHealth Corp. (Nasdaq: DRIO)* has a significant new agreement with a Blue Cross Blue Shield (BCBS) health plan, marking a pivotal expansion in the fast-growing digital health landscape. This move integrates Dario's AI-driven cardiometabolic digital health solutions, covering diabetes, hypertension, and weight management, into the offerings of one of America’s most trusted health insurers. According to a recent , the cardiometabolic disease market is projected to surpass $1.2 trillion by 2033.

According to the company, the BCBS partnership, launched in January 2025, is already contributing to Dario's recurring revenue growth and is expected to expand throughout the year. This adds to Dario's impressive roster of nine health plan clients, including national and regional payers, and 12 Fortune 500 companies, according to the company.

Financial momentum seemingly remains strong, with Q3 2024 revenue up 111% YoY, driven by operational efficiencies post-Twill acquisition. A $25.6 million private placement has boosted Dario's cash position to $40.6 million, supporting growth strategies. The company targets operational cash flow positivity by mid-2025.

Recently, the company also reported another potential key growth driver -- Dario's expansion into the booming $100 billion GLP-1 weight-loss market. Notably, unlike competitors, Dario offers an end-to-end solution that integrates GLP-1 prescriptions with behavioral health tools, enhancing long-term outcomes. Strategic collaborations, such as with MediOrbis, further strengthen this offering.

Dario’s data-driven approach delivers measurable results: 5x ROI for payers, a 58% reduction in hyperglycemic events, and a 59% decrease in anxiety symptoms. Its scalable, AI-powered platform is rapidly gaining traction among payers and employers seeking cost-effective, high-impact health solutions.

With a presence in multi-billion-dollar markets, expanding health plan partnerships, strong financials, and cutting-edge technology, DarioHealth is positioning itself as a potential digital health powerhouse in the making.

Recent News from Dario:

* Disclaimer: Nothing in this report constitutes financial or investment advice, nor does it represent an offer to buy or sell securities. This report is published by Market News Alerts, a brand which is part of the Wall Street Wire™ network. The operators of Wall Street Wire are not registered brokers, dealers, or investment advisers. This report contains paid promotional content related to DarioHealth and was produced as part of their paid subscription to Wall Street Wire. This report has not been reviewed or approved by DarioHealth prior to publication. Please review the full disclaimers and compensation disclosures : .

EN
07/02/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on DarioHealth

 PRESS RELEASE

Market Alert: Hinge Health's Multi-Billion Dollar Expected IPO Highlig...

NEW YORK--(BUSINESS WIRE)-- Market News Alerts Reports: DarioHealth Corp. (Nasdaq: DRIO)* emerges as a potential hidden gem in digital health as competitor Hinge Health prepares to go public at a multi-billion-dollar valuation, highlighting a dramatic valuation gap that savvy investors are beginning to notice. With Hinge Health filing for a potential April IPO at a valuation that according to recent reports could reach $3-6 billion despite recent market volatility, DarioHealth's comprehensive AI-driven chronic care platform appears to be potentially significantly undervalued by comparison. Fi...

 PRESS RELEASE

Market News Alert: DarioHealth Beats Q4 Expectations, Reports 398% Gro...

NEW YORK--(BUSINESS WIRE)-- Market News Alerts Updates: Market News Alerts Reports: DarioHealth Corp. (Nasdaq: DRIO) reported fourth quarter revenue of $7.6 million, beating analyst consensus of $7.39 million. B2B2C recurring revenue surged 398% year-over-year to $5.6 million in Q4, driven by rapid employer and health plan adoption of the company's comprehensive chronic care platform. Gross margins in the B2B2C business exceeded 80% over the past three quarters. Full-year 2024 revenue reached $27.0 million, up 32.9% from 2023, while Q4 operating loss decreased by 35% compared to Q1 2024. The ...

 PRESS RELEASE

Market News Alert: DarioHealth Secures Significant New Agreement, Expa...

NEW YORK--(BUSINESS WIRE)-- Market News Alerts Updates: DarioHealth Corp. (Nasdaq: DRIO)* has a significant new agreement with a Blue Cross Blue Shield (BCBS) health plan, marking a pivotal expansion in the fast-growing digital health landscape. This move integrates Dario's AI-driven cardiometabolic digital health solutions, covering diabetes, hypertension, and weight management, into the offerings of one of America’s most trusted health insurers. According to a recent , the cardiometabolic disease market is projected to surpass $1.2 trillion by 2033. According to the company, the BCBS part...

 PRESS RELEASE

PESG Report: DarioHealth Positions Itself as a Market Leader in the Mu...

NEW YORK--(BUSINESS WIRE)-- PESG Releases Report: In a healthcare market brimming with potential, DarioHealth Corp. (Nasdaq: DRIO)* is quietly emerging as a standout player, combining cutting-edge technology with proven outcomes. Looking at recent achievements, it seems DarioHealth’s multi-condition digital health platform and its accelerating financial trajectory may position it as a sleeper hit in a rapidly growing sector. Breaking Down the Opportunity At the heart of DarioHealth’s success is its integrated chronic care platform—a solution tailored to tackle some of the costliest and mos...

 PRESS RELEASE

DarioHealth Expands GLP-1 Weight-Loss Solution, Unlocking New Revenue ...

NEW YORK--(BUSINESS WIRE)-- Market News Alerts Updates that DarioHealth Corp. (Nasdaq: DRIO) is taking another bold step into the rapidly growing weight-loss market, now to exceed $100 billion annually by 2030. The company’s latest expands its GLP-1 offering with prescribing capabilities, positioning Dario to capture a larger share of this lucrative space as demand for medical weight-loss solutions skyrockets across employers and consumers. Following the announcement, Dario’s shares surged nearly 14%, reflecting investor excitement over this significant growth opportunity. The market for G...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch